I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.

Slides:



Advertisements
Similar presentations
Wyoming Department of Health-Communicable Diseases
Advertisements

Wednesday, May 15 th 1:00 p.m. – 1:30 p.m.. Dr. I. Jean Davis, PhD, DC, PA, AAHIVS.
Initiating Antiretroviral Therapy in Treatment-Naive Patients Charles B. Hicks, MD Associate Professor of Medicine, Division of Infectious Diseases and.
John W. Hogan, M.D. Howard University College of Medicine.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
BVCOG HRSA/HAB Tier 2 and 3 Performance Measures Lisa Cornelius, MD, MPH July 2010.
Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute
I. Jean Davis, PhD, PA, AAHIVS Howard University College of Medicine.
I. Jean Davis, PhD, PA, AAHIVS Howard University College of Medicine.
SUBSTANCE ABUSE & HIV DISEASE Janet L. Mitchell, M.D., M.P.H., F.A.C.O.G. Consultant on Women’s Health Addiction, Research & Treatment Corporation Brooklyn,
I. Jean Davis, PhD, PA, AAHIVS Howard University College of Medicine.
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.
Skin and Oral Manifestations of HIV Infection
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU August 27, 2014.
2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.
Bloodborne Pathogens HIV, AIDS, and Hepatitis Unit 1.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
October E-learn Call: Visual Design for Powerful Presentations Sophy Wong (East Bay AETC)
NYU Medical Grand Rounds Clinical Vignette Matthew B. Brown M.D. PGY-2 10/4/11 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Adult Viral Hepatitis Update Roxanne Ereth, MPH, BS Hepatitis C Program Manager Adult Viral Hepatitis Prevention Coordinator.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Basic Facts StatisticsSymptoms Random Knowledge Myth or Fact.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
HIV Organ Policy Equity (HOPE) Act Research Criteria: follow-up discussion Advisory Committee on Organ Transplantation April 13, 2015.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
November  HIV stands for Human Immunodeficiency Virus  It is a virus that attacks the immune system and weakens the body’s ability to fight infection.
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
Two Men with Extensive Genital Ulcer Disease Recent Cases at the Denver Metro Health Clinic.
John W. Hogan, M.D Howard University College of Medicine.
1 Diagnosis of HIV Infection in Children HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Mr X and Mr Y 1 Case 4: July year-old Caucasian man ‘Mr X’ 2.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Immigration Removal Centres and HIV Clinical Care Jane Anderson Homerton University Hospital NHS Foundation Trust.
1 Mosby items and derived items © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier, Inc. Infection and Human Immunodeficiency Virus Infection Chapter.
Metabolic Syndrome in HIV- Infected Patients from MTCT-Plus, Thai Outpatient Population J. JANTARAPAKDE1,2,*, C. CHATURAWIT1,2, S. PENGNONYANG1,2, W. PIMA1,
Glomerular lesions in HIV-1-infected patients: evolution from 1996 to 2007 on 88 consecutive renal biopsies. Clara Flateau, François-Xavier Lescure, Emmanuelle.
HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU Sept 1, 2015.
Human Immunodeficiency Virus (HIV) This virus causes HIV infection and AIDS The HIV infected person may, or may not have AIDS. They may, or may not, have.
President’s Emergency Plan for AIDS Relief 2006 Semi-Annual Program Results (SAPR) October 1, 2005 – March 31, 2006.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Mary Lawrence Hicks, FNP Positive Health Program October 21, 2010.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
Transplantation in HIV Michelle Roland, MD Assistant Professor of Medicine UCSF Positive Health Program at SFGH.
Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.
1 Management, Care for infants who were born from infected mothers HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV Care Continuum New Diagnoses, 2011, Georgia. Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States Percent
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
Interventions for Clients with HIV/AIDS and Other Immunodeficiencies.
New Developments in HIV Kerri Howley Coordinator – The Green Room
Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,
1 Chapter 35 HIV- and AIDS-Related Drugs Copyright © 2015, 2012, 2009, 2006, 2003, 2000, 1997, 1993 by Saunders, an imprint of Elsevier Inc.
Problems of HIV Infection in the HAART Era Akihiko Suganuma M.D. Tokyo Metropolitan Komagome Hospital Department of Infectious Diseases.
Henry Masur, MD Bethesda, Maryland
Learning objectives Define HIV treatment goals
Keio University of School of Medicine
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Jeopardy Game Hosted by PHDP Jamaica MODULE 4 Treatment Literacy.
Hiv.
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project

 Discuss the benefits of Antiretroviral Therapy in reducing mortality and/or AIDS-related morbidity.  Discuss the role of ART in reducing the risk of disease progression in individuals infected with HIV.  Discuss the role of ART in the prevention of transmission of HIV for individuals infected with HIV.

 Mr. Wilson is a 35 year old Black male, diagnosed with HIV 5 years ago. He initiated a medication regimen at the time of diagnosis, but returned to IV drug abuse 3 years ago and was lost to care. The patient denies a history sexual activity with men. He states that he acquired HIV while injecting drugs. He does not recall the name of the ART, but states he was taking at least 2 medications.  Patient has been married for 1 year. His wife is a case manager at the substance abuse center where he “resolved his need to use drugs”, 2 years ago.  Mr. Wilson states he has mild high blood pressure and started taking Dyazide over a year ago. He was told he had borderline diabetes. He states he has never taken medication for his diabetes. He has a family history of cardiovascular disease, diabetes and cancer. His eldest brother had both legs amputated 4 years ago at age 62 and died last year due to complications.

Inpatient Management Serologic OI HAART Testing Prophylaxis Outpatient Management

 Less than one-third of HIV-infected individuals in the United States have suppressed viral loads.  Despite remarkable improvements in HIV treatment and prevention, economic and social barriers resulting in:  Morbidity  Mortality  HIV infections persist

 The evaluation of Initiating or Restarting Therapy should include:  a discussion on the benefits of antiretroviral therapy (ART)  The following laboratory tests performed during patient visits can be used to stage HIV disease and to assist in the selection of ARV drug regimens:  HIV antibody testing  CD4 T-cell count (CD4 count)  Plasma HIV RNA (viral load)  Complete blood count, chemistry profile, transaminase levels, blood urea nitrogen (BUN), and creatinine, urinalysis, and serologies for hepatitis A, B, and C viruses  Fasting blood glucose and serum lipids  Genotypic resistance testing

 ART has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV disease into a chronic, manageable condition.  Patients should also be told that untreated HIV infection will eventually lead to immunological deterioration and increased risk of clinical disease and death.

 HIV-associated immune deficiency, the direct effects of HIV on end organs, and the indirect effects of HIV associated inflammation on these organs all most likely contribute to HIV-related morbidity and mortality.  Untreated HIV infection may have detrimental effects at all stages of infection.  ART is beneficial even when initiated later in infection.  Sustaining viral suppression and maintaining higher CD4 count may delay, prevent, or reverse some non-AIDS-defining complications:  HIV associated kidney disease  Liver disease  CVD  Neurologic complications  Malignancies

 In addition, effective treatment of HIV- infected individuals with ART is highly effective at preventing transmission to sexual partners.  Clinicians should also inform patients that viral suppression from effective ART can reduce the risk of sexual transmission to others.

 Mr. Wilson is a 35 year old Black male, diagnosed with HIV 5 years ago. He initiated a medication regimen at the time of diagnosis, but returned to IV drug abuse 3 years ago and was lost to care. The patient denies a history sexual activity with men. He states that he acquired HIV while injecting drugs. He does not recall the name of the ART, but states he was taking at least 2 medications.  Patient has been married for 1 year. His wife is a case manager at the substance abuse center where he “resolved his need to use drugs”, 2 years ago.  Mr. Wilson states he has mild high blood pressure and started taking Dyazide over a year ago. He was told he had borderline diabetes. He states he has never taken medication for his diabetes. He has a family history of cardiovascular disease, diabetes and cancer. His eldest brother had both legs amputated 4 years ago at age 62 and died last year due to complications.

 What additional history do we need?  What lab tests should we order?  What co-morbidities are our concerns?  What impact would ART have on his quality of life and health?  What health promotion, disease prevention education would you provide for Mr. Wilson?

Howard University HURB th Street NW, 2 nd Floor Washington, DC (Office) (Fax)